Collaborating Across the Continuum™: Taking IgA Nephropathy Management to the Next Level
Released On
January 31, 2023
Expires On
January 31, 2024
Media Type
Internet
Completion Time
90 minutes
Specialty
Nephrology, Pharmacy, Primary Care
Topic(s)
Kidney disorders
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Travere Therapeutics.
Credit Available
- Physicians — maximum of 1.5 AMA PRA Category 1 Credits™
- Nurses — 1.5 Contact Hours
- Pharmacists — 1.5 Contact Hours (0.10 CEUs)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is intended for nephrologists, primary care providers, specialty pharmacists, managed care professionals, nurse practitioners, physician assistants, registered nurses, and other members of the IgAN care team.
Activity Overview
Immunoglobulin (Ig) A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, and it is considered a significant cause of end-stage renal disease (ESRD) in young adults. The precise pathogenesis of IgAN remains unclear. The clinical and pathological features vary significantly between individuals and races, which makes treating IgAN challenging. In most cases, the therapeutic strategies in IgAN are optimal blood pressure control and proteinuria remission to improve the renal functions. Immunosuppressive agents, such as corticosteroids, can be considered in patients with persistent proteinuria and a high risk of renal function decline; however, they include a high toxicity profile.
Various pharmacological therapeutic targets are emerging based on the evolving understanding of the autoimmune pathogenesis of the progression of IgAN, which involves the immune response, mucosal immunity, renal inflammation, complement activation, and autophagy. In this online activity, expert faculty provide information to help health care providers stay up to date on recent findings regarding the pathophysiology of IgAN, and the efficacy and safety profiles of available and emerging agents.
Learning Objectives
- Upon successful completion of this activity, you should be better prepared to:
-
- Assess the pathophysiology of the disease progression of IgAN as potential targets for novel therapy
- Summarize recent evidence-based guidelines for the management of IgAN
- Analyze recent efficacy and safety trial data on new and emerging treatment for IgAN
- Design individualized treatment plans for patients with IgAN based on principles of multidisciplinary care
Faculty
Richard Lafayette, MD, FACP
Professor, Medicine (Nephrology)
Director, Glomerular Disease Center
Stanford University Medical Center
Stanford, CA
Whitney Simmons, APRN-CNP, IgCN
Community Outreach Coordinator and Patient Ambassador for the IgA Nephropathy Foundation
Current Board Member of the IgA Nephropathy Medical and Scientific Advisory Board
Mosaic Infusion Solutions
Oklahoma City, OK
Michelle M. Richardson, PharmD, BCPS
Special and Scientific Staff
William B. Schwartz Division of Nephrology
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, MA
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.10 CEUs) under the ACPE universal activity number 0290-0000-23-023-H01-P. The activity is available for CE credit through January 31, 2024.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
- Richard Lafayette, MD, FACP
-
- Grant/Research Support: Alexion, Appellis, Calliditas, Chinook, Omeros, Otsuka, Pfizer, Travere
- Consultant: Alexion, Calliditas, Chinook, GSK, Novartis, Omeros, Otsuka, Pfizer, Travere
Whitney Simmons, APRN-CNP, IgCN, has no relevant financial relationships with ineligible companies.
Michelle M. Richardson, PharmD, BCPS, has no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.